---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-014987"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:42:30.230057+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs reports FY2025 net loss $48.8M; SL-325 Ph1 data expected Q2 2026

## Summary
- Net loss for FY2025 was $48.8M ($0.70/diluted share), vs $75.4M ($1.49) in FY2024.
- Cash and investments at Dec 31, 2025 were $78.1M; after $21.4M ATM raise in Q1 2026, pro forma cash ~$94.5M.
- SL-325 Phase 1 in healthy volunteers nearly complete; data expected Q2 2026, Phase 2 in Crohn's planned Q3 2026.
- R&D expenses fell to $35.3M from $67.2M, driven by discontinuation of SL-172154 program.
- Michael Choi, M.D., appointed VP of Clinical Development; cash runway guidance extended into 2029.

## SEC filing metadata
- accession: 0001628280-26-014987
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000162828026014987/0001628280-26-014987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000162828026014987/sttk-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-014987
- JSON: https://secwatch.observer/filing/0001628280-26-014987.json
- Plain text: https://secwatch.observer/filing/0001628280-26-014987.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.